278 related articles for article (PubMed ID: 28109565)
1. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
2. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
3. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of the efficacy of N-acetylcysteine in the treatment of acute exacerbation of chronic obstructive pulmonary disease.
Jiang C; Zou J; Lv Q; Yang Y
Ann Palliat Med; 2021 Jun; 10(6):6564-6576. PubMed ID: 34237968
[TBL] [Abstract][Full Text] [Related]
6. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of
Huang C; Kuo S; Lin L; Yang Y
Ther Adv Respir Dis; 2023; 17():17534666231158563. PubMed ID: 36927162
[TBL] [Abstract][Full Text] [Related]
8. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
9. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral N-acetylcysteine on COPD patients with microsatellite polymorphism in the heme oxygenase-1 gene promoter.
Zhang JQ; Zhang JQ; Fang LZ; Liu L; Fu WP; Dai LM
Drug Des Devel Ther; 2015; 9():6379-87. PubMed ID: 26674585
[TBL] [Abstract][Full Text] [Related]
11. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
13. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.
Sutherland ER; Crapo JD; Bowler RP
COPD; 2006 Dec; 3(4):195-202. PubMed ID: 17361500
[TBL] [Abstract][Full Text] [Related]
16. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.
Stav D; Raz M
Chest; 2009 Aug; 136(2):381-386. PubMed ID: 19447919
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of the herbal formula Buzhong Yiqi Tang for stable chronic obstructive pulmonary disease.
Chen Y; Shergis JL; Wu L; Yu X; Zeng Q; Xu Y; Guo X; Zhang AL; Xue CC; Lin L
Complement Ther Med; 2016 Dec; 29():94-108. PubMed ID: 27912964
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
19. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
[TBL] [Abstract][Full Text] [Related]
20. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
